Impact of Dual Lipid-Lowering on Coronary Plaque
Among Japanese patients who underwent PCI, aggressive lipid-lowering with dual inhibition of cholesterol synthesis and absorption produced stronger coronary plaque regression compared with sole inhibition of the cholesterol biosynthetic pathway. Combination therapy with statin plus ezetimibe might thus be a promising lipid-lowering option for high-risk patients.
Conclusions
Among Japanese patients who underwent PCI, aggressive lipid-lowering with dual inhibition of cholesterol synthesis and absorption produced stronger coronary plaque regression compared with sole inhibition of the cholesterol biosynthetic pathway. Combination therapy with statin plus ezetimibe might thus be a promising lipid-lowering option for high-risk patients.
SHARE
